Ketogenic diets in children with intractable epilepsy and its effects on gastrointestinal function, gut microbiome, inflammation, and quality of life.

Abstract

The ketogenic diet (KD) is a treatment for children with intractable epilepsy (IE), it can cause gastrointestinal symptoms, and have an adverse effect on growth, nutrition and quality of life (QOL). This study investigated the extent of these side-effects by comparing children with IE on KDs to their counterparts on normal diets. Patients with IE were categorised into patients with KD or control groups. Gastrointestinal side effects and QOL were assessed using the PedsQL™ Gastrointestinal Symptoms Module. Cross sectional growth, gut microbiome compositions and inflammation levels were also analysed. Fourteen patients on the KD and 13 control patients were enrolled. Patients had been on KD for a median duration of 15 months (Interquartile range (IQR): 9.8 to 60 months). The patients on the KD reported a trend to lower total gastrointestinal symptoms scores (more symptoms) compared to control patients, at 71.1 and 84.9 respectively (p=0.06, not significant). Patients on the KD had significantly lower QOL scores compared to control patients(p=0.01). Patients on the KD were found to have consistently lower median height/length, weight and Body mass index (BMI) z scores compared to the controls although these were not statistically significant. Patients on the KD had a lower microbial diversity, Both groups had a normal level of S100A12, a marker of gut inflammation. Patients on the KD reported a trend to more gastrointestinal symptoms and more QOL concerns compared to controls. Although microbial differences were noted in patients on the KD, this did not result in detectable gut inflammation.